NewLimit Raises $435 Million to Develop Cellular Aging Reversal Therapy

Biotech startup NewLimit has successfully closed a $435 million funding round following its announcement of a pioneering prototype drug that reverses liver cell aging. This breakthrough promises to advance the field of longevity medicine significantly.